Scarica l'app Stockscreener
0.7089
8.60%
-0.0667
Dopo l'orario di chiusura:
.70
-0.0089
-1.26%
Precedente Chiudi:
$0.7756
Aprire:
$0.694136
Volume 24 ore:
321.00K
Relative Volume:
0.07
Capitalizzazione di mercato:
$21.41M
Reddito:
-
Utile/perdita netta:
$-29.77M
Rapporto P/E:
-0.0463
EPS:
-15.2954
Flusso di cassa netto:
$-24.23M
1 W Prestazione:
+10.77%
1M Prestazione:
+158.82%
6M Prestazione:
-59.72%
1 anno Prestazione:
-80.09%
Intervallo 1D:
$0.6871
$0.7163
Intervallo di 1 settimana:
$0.655
$0.96
Portata 52W:
$0.25
$3.7044
Moleculin Biotech Inc Stock (MBRX) Company Profile
Nome
Moleculin Biotech Inc
Settore
Industria
Telefono
713-300-5160
Indirizzo
5300 MEMORIAL DRIVE, HOUSTON, TX
Confronta MBRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MBRX
Moleculin Biotech Inc
|
0.7089 | 23.43M | 0 | -29.77M | -24.23M | -15.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.95 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.39 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.64 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
575.42 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.83 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-09 | Ripresa | H.C. Wainwright | Buy |
| 2025-02-12 | Downgrade | Maxim Group | Buy → Hold |
| 2022-07-18 | Ripresa | Oppenheimer | Outperform |
Moleculin Biotech Inc Borsa (MBRX) Ultime notizie
Moleculin Biotech Inc. Stock Analysis and ForecastTremendous portfolio expansion - Autocar Professional
Is Moleculin Biotech Inc. a good long term investmentConsistent triple-digit returns - jammulinksnews.com
Moleculin Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference - GlobeNewswire
Moleculin Participates in the Virtual Investor 'What’s Your Story” Summer Spotlight On-Demand Conference - The Manila Times
Exclusive: Moleculin CEO Shares Vision Behind Revolutionary Cancer Drug Pipeline in New Investor Presentation - Stock Titan
Moleculin Biotech Gains Approval for Phase 2B/3 AML Study - MSN
What drives Moleculin Biotech Inc. stock priceConsistently high returns - Autocar Professional
What analysts say about Moleculin Biotech Inc. stockMassive wealth growth - jammulinksnews.com
Moleculin Biotech Appoints Adriano Treve as Strategic Advisor - The Globe and Mail
MBRX Surges 29.65% on Strategic Hire and Phase 3 Momentum – Is This the Catalyst for a Biotech Breakout? - AInvest
Moleculin appoints former Roche executive as strategic advisor - Investing.com Australia
Moleculin appoints former Roche executive as strategic advisor By Investing.com - Investing.com Canada
Moleculin Biotech, Inc. Appoints Adriano Treve as Strategic Advisor to Enhance Partnerships and Advance Clinical Trials - Nasdaq
Moleculin Engages Industry Veteran Adriano Treve to Explore Accelerated Strategic Partnerships - GlobeNewswire
What makes Moleculin Biotech Inc. stock price move sharplySmart Trading With Safety Margin - Newser
Why Moleculin Biotech Inc. stock attracts strong analyst attentionTriple Digit Return Forecasts - Newser
Moleculin Biotech Surges 19.5%—What's Fueling the Rally? - AInvest
Moleculin Biotech enters $6.5 million at-the-market equity offering agreement By Investing.com - Investing.com South Africa
Moleculin Biotech Enters New Stock Offering Agreement - TipRanks
Moleculin Biotech enters $6.5 million at-the-market equity offering agreement - Investing.com
Moleculin Acquires $2M Private Grant for Brain Tumor Trial at MD Anderson - BioTecNika
Moleculin Expands Phase 3 MIRACLE Clinical Trial into the Country of Georgia, Enrollment Update and Future Plans - GlobeNewswire
Moleculin receives Georgian approval for pivotal AML treatment trial By Investing.com - Investing.com India
Moleculin receives Georgian approval for pivotal AML treatment trial - Investing.com Australia
Moleculin Biotech Stock Soars 13.44% on Clinical Trial Expansion - AInvest
Moleculin Biotech, Inc. Secures RAMPA Approval for Phase 2B/3 MIRACLE Trial in Georgia, Expanding Clinical Recruitment Efforts - Nasdaq
MBRX gains RAMPA nod for pivotal Phase 2B/3 AnnAraC AML trial | THTX SEC FilingForm 6-K - Stock Titan
Moleculin's Phase 3 AML Treatment Trial Gains Momentum: 7 Patients Treated, 16 New Sites Coming - Stock Titan
Favourable Signals For Moleculin Biotech: Numerous Insiders Acquired Stock - simplywall.st
Moleculin Biotech (MBRX) Price Target Reduced to $13 by Roth Cap - GuruFocus
Moleculin Biotech Faces Nasdaq Delisting Warning - TipRanks
Healthcare Stocks to Watch: Catalyst Pharmaceuticals, AVITA Medical, and Moleculin Biotech. - AInvest
Moleculin Biotech Raises $5.9M in Public Offering - TipRanks
Health Care Stocks Stumble Amid Market Adjustments - Finimize
Moleculin Biotech prices 16.08M shares at 37c in public offering - Yahoo Finance
Moleculin Biotech prices $5.9M public offering; shares down about 47% - MSN
Moleculin Biotech's 50% Plunge Explained: Technical Sell-Off Dominates - AInvest
Moleculin Biotech (NASDAQ:MBRX) Given Buy Rating at HC Wainwright - Defense World
Moleculin Biotech (MBRX) Rating Reiterated with $4.00 Price Target | MBRX Stock News - GuruFocus
Moleculin Receives Positive FDA Feedback on Pediatric Study Plan - GuruFocus
Moleculin Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children with R/R AML - GlobeNewswire
Moleculin Biotech Inc Azioni (MBRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.91%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):